/
ANTX
$5.03-$0.17 (-3.27%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$187.3M
36M shares
52-week range
$1.00 – $6.91
68% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
2.60%
Moderate
Price (6 mo)
Loading chart…
Change$-10.37
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $77.0K | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | −$77.0K | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $29.3M | $6.0M | $16.9M | $29.5M | $54.9M | $40.5M | $24.8M |
| Operating income | −$31.1M | −$7.3M | −$21.6M | −$42.3M | −$69.6M | −$54.6M | −$38.1M |
| EBITDA | $0 | −$6.3M | −$21.5M | −$40.9M | $4.9M | $3.2M | −$35.2M |
| Net income | −$33.8M | −$13.6M | −$21.5M | −$41.0M | −$64.7M | −$51.3M | −$35.2M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | -0.30 | -0.78 | -1.50 | -2.79 | -2.74 | -1.72 | -1.16 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $73M | $-0.96 | $-0.96–$-0.96 | 1 |
| 2027 | $217M | $-1.04 | $-1.04–$-1.04 | 1 |
| 2028 | $390M | $-1.02 | $-1.02–$-1.02 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.59
Price
$5.03
Implied downside
-88%
Peer comparison
AN2 Therapeutics, Inc. Common Stock
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
www.an2therapeutics.com- Employees
- 21
- IPO / List date
- Mar 25, 2022
- HQ
- MENLO PARK, CA
Held by traders on TradeandTell
No one on the platform currently holds ANTX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 198,800 | $679.9K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ANTX yet.
